WeTrials
Recruiting

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

What is this study?

This study is testing a new combination of two drugs, SAR444881 and cemiplimab, to see how well they work against solid tumors. Researchers want to understand specific biological signs, called biomarkers, that show how the body responds to these treatments.

Who can participate?

You may be able to join if you are 18 or older and have an advanced tumor or cancer that has spread. However, you cannot join if you are pregnant, have certain active immune system disorders, or have severe allergies to similar medications.

What will happen?

Participants will receive the study medications and have regular check-ups with the medical team to monitor their health and response to the treatment. The team will also look closely at biological samples to learn how the drugs are working.

Where and when?

This study is currently open and actively looking for participants. It is taking place in Houston, Texas, in the United States.

Key Points
  • 1Tests an investigational drug combined with an immunotherapy treatment
  • 2Open to adults with advanced solid tumors or cancers
  • 3Currently recruiting patients in Houston, Texas

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.